Literature DB >> 2427855

Effects of celiprolol on reflex control of the cardiovascular system in essential hypertension.

G Mancia, G Grassi, G Parati, G Pomidossi, E Sabadini, C Giannattasio, G Bolla, A Zanchetti.   

Abstract

We have previously shown that baroreceptor control of the cardiovascular system and the cardiopulmonary receptor control of peripheral circulation are preserved or only moderately reduced during antihypertensive treatment with acebutolol or nadolol, which indicates that treatment with beta blockers with or without intrinsic sympathomimetic activity does not impair fundamental neural mechanisms involved in circulatory homeostasis. In the present study we have investigated the reflex control of circulation before and during antihypertensive treatment with celiprolol, which, in addition to its beta-blocking action, has vasodilator properties that may stem from interference with neural cardiovascular control. In six essential hypertensive subjects we measured blood pressure (intraarterial catheter), heart rate (ECG recording), central venous pressure (right atrial catheter), and forearm blood flow and resistance (plethysmography) before and during alterations in the activity of the arterial baroreceptors obtained by means of lower body suction and passive leg raising. The study was performed before and after 5-7 days of oral administration of celiprolol at 200-400 mg once a day. Compared to the values obtained in the control, condition celiprolol caused a reduction in blood pressure, a slight change in heart rate, and an increase in forearm blood flow, which indicated the occurrence of a clear-cut forearm vasodilatation. The heart rate responses to arterial baroreceptor manipulation were unchanged by celiprolol which reset the carotid baroreflex so that its tonic restraint on blood pressure increased despite the hypotension induced by the drug. The inhibitory restraint tonically exerted by the cardiopulmonary receptors on peripheral circulation was also increased by celiprolol.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2427855     DOI: 10.1097/00005344-198608004-00013

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  12 in total

Review 1.  Efficacy of celiprolol in hypertension and angina pectoris. Introduction.

Authors:  R J Norris
Journal:  Cardiovasc Drugs Ther       Date:  1991-01       Impact factor: 3.727

2.  Haemodynamic effects of new beta-blockers with vasodilatory properties in essential hypertension.

Authors:  H Tsukiyama; K Otsuka; M Horii
Journal:  Drugs       Date:  1988       Impact factor: 9.546

3.  Reliability of blood pressure determination with the Finapres with altered physiological states or pharmacodynamic conditions.

Authors:  D McAuley; B Silke; S Farrell
Journal:  Clin Auton Res       Date:  1997-08       Impact factor: 4.435

4.  Hemodynamic effects of celiprolol at rest and during exercise; a comparison with enalapril.

Authors:  S Ghiringhelli; E Cozzi; D Tsialtas
Journal:  Cardiovasc Drugs Ther       Date:  1988-07       Impact factor: 3.727

Review 5.  Celiprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cardiovascular disease.

Authors:  R J Milne; M M Buckley
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

6.  Effect of celiprolol on large and small arteries of the forearm circulation in hypertensive patients.

Authors:  O Roman; N Meza; C Klenner
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

7.  Effect of pretreatment with the selective beta 1-adrenoceptor antagonist bisoprolol on the subsequent cardiovascular actions and beta-adrenoceptor subtype specific occupancy of celiprolol in healthy man.

Authors:  C de Mey; K Beithaupt; D Palm; U Fuhr; G G Belz
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

8.  A placebo controlled comparison of the effects of metoprolol and celiprolol on echo-Doppler measurements of cardiovascular function in normal volunteers.

Authors:  B Silke; A Thompson; A Leitch; J G Riddell
Journal:  Br J Clin Pharmacol       Date:  1995-07       Impact factor: 4.335

Review 9.  A risk-benefit assessment of celiprolol in the treatment of cardiovascular disease.

Authors:  M J Kendall; I Rajman
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

Review 10.  Celiprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in hypertension and angina pectoris.

Authors:  J G Riddell; R G Shanks; R N Brogden
Journal:  Drugs       Date:  1987-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.